Artificial intelligence-enabled technology tools are capable of dissecting large quantities of data faster than ever before and in some cases, in real time. However, the increasingly widespread use of AI challenges regulators to balance the benefits of innovation while protecting patient safety, health and privacy rights.
An Intellectual Property & Technology Law Journal article on the future of AI in life sciences provides a cross-border analysis of the evolving regulatory landscape in the U.S., Europe and China that seeks to respond to technology advances that may revolutionize all facets of research and development and health care delivery.
The authors observe that while the law has trailed invention in this area, regulators in these key jurisdictions have been trending towards a more harmonized global approach. Current trends suggest that AI and machine learning-enabled devices represent an increasingly important component of the life sciences sector, but whether regulation can evolve at the pace of innovation remains to be seen.
The article was authored by partner and head of European life sciences Lincoln Tsang, life sciences partner Katherine Wang, life sciences regulatory & compliance partner Kellie Combs, life sciences regulatory & compliance counsel Sarah Blankstein, health care associate Julie Kvedar, with contributions from trainee solicitor William Radcliffe.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.